AbCellera Biologics, Inc. ABCL

VANCOUVER, British Columbia, September 16, 2026--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

VANCOUVER, British Columbia, September 02, 2026--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial results from its drug candidate for hot flashes in menopausal women. On Friday alone, the stock climbed to its highest price in three years of […]

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]

VANCOUVER, British Columbia, August 13, 2026--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency and severity of moderate-to-severe menopausal hot flashes versus placebo while showing a favorable tolerability profile over four weeks. By pairing these data with improvements in sleep and patient-reported outcomes, ABCL635 positions AbCellera as an emerging player in the large, under-served...

The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research that follows recent clinical data and new partnership agreements. These developments have prompted several firms to revisit their rating and price target work on the stock. Read on to see how these changing assumptions fit into the broader narrative and how you can track the story from...

Why ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase 2 trial for menopause related hot flashes. The single dose of ABCL635 produced statistically significant reductions in both the frequency and severity of vasomotor symptoms versus placebo and was reported as well tolerated, with additional benefits in sleep and patients’ overall perception of...

VANCOUVER, British Columbia, August 11, 2026--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms. The trial shows clinically significant improvement in vasomotor symptoms from a single dose of ABCL635. ABCL635 represents the first clinical success from AbCellera's internal pipeline and supports its GPCR and ion channel antibody discovery platform. The outcome may influence AbCellera's future plans for internal...

AbCellera Biologics stock has surged year to date, yet the company scores poorly on broad valuation checks and currently screens as expensive on market multiples. After a strong run supported by positive clinical news, investors are weighing whether the recent share price strength already reflects much of the good news. Year to date, AbCellera Biologics has delivered a very large 172.3% return, which puts extra focus on whether the current price offers enough margin for error. The recent...